Department of Orthopaedic Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Orthop Surg. 2021 Jul;13(5):1602-1608. doi: 10.1111/os.13014. Epub 2021 Jun 14.
To investigate the clinical effect of mouse nerve growth factor (mNGF) and methylcobalamin (MeCbl) for the treatment of lumbar disk herniation (LDH) with foot drop.
A total of 46 patients suffering from LDH with foot drop who underwent transforaminal lumbar interbody fusion (TLIF) surgery in our department from January 2015 to December 2017 were retrospectively analyzed. We divided these patients into two groups according to the different postoperative treatment which independently selected by patients after signing informed consent form: one group of 25 patients was treated with MeCbl alone (Group MeCbl), the other group of 21 patients was treated with a combination of mNGF and MeCbl (Group MeCbl+mNGF). Patient demographics, the visual analogue scale (VAS) scores, sensory and muscular strength improvement statistics at 1 week, 4 weeks, 12 weeks, and 12 months postoperatively were recorded. Motor/sensory deficits, sciatica and overall neurological outcome after treatment of MeCbl alone and combination of mNGF and MeCbl were retrospectively analyzed.
The follow-up ranged between 12 and 42 months (mean 20.8 months). There were no significant differences between these two groups of patients with respect to sex ratio, age, smoking, diabetes, disease course, section of protruding disc(s), muscular strength of foot dorsiflexion or preoperative visual analogue scale (VAS) score (P > 0.05). The VAS scores of Group MeCbl+mNGF were significantly lower than Group MeCbl at 1 week, 4 weeks, 12 weeks, and 12 months postoperatively (4.32 ± 0.75 vs 5.25 ± 0.79,2.65 ± 0.48 vs 3.42 ± 0.52, 1.72 ± 0.36 vs 2.45 ± 0.39, 1.12 ± 0.22 vs 1.52 ± 0.24, P < 0.05). The effective rates of sensory improvement were significantly higher in Group MeCbl+mNGF compared with Group MeCbl at 12-week/12-month follow-up time point (90.48% vs 52.00%,95.24% vs 68.00%, P < 0.05). The effective rate of muscular strength improvement of the two groups did not differ significantly at 1 week after surgery but exhibited statistically significant differences at subsequent time points (61.90% vs 32.00%, 76.19% vs 44.00%, 80.95% vs 48.00%, P < 0.05).
Application of mNGF had clinical effects on promoting the recovery of neurological function in patients suffering from LDH with foot drop.
观察鼠神经生长因子(mNGF)联合甲钴胺(MeCbl)治疗腰椎间盘突出症(LDH)合并足下垂的临床疗效。
回顾性分析 2015 年 1 月至 2017 年 12 月我科收治的 46 例行椎间孔镜下腰椎间盘切除术(TLIF)治疗的 LDH 合并足下垂患者的临床资料,根据患者签署知情同意书后自主选择的不同术后治疗方案分为甲钴胺组(25 例,MeCbl 组)和 mNGF 联合甲钴胺组(21 例,MeCbl+mNGF 组)。记录两组患者一般资料、术后 1 周、4 周、12 周、12 个月的视觉模拟评分(VAS)、感觉及肌力改善情况,比较甲钴胺组与 mNGF 联合甲钴胺组治疗后运动/感觉功能障碍、坐骨神经痛及总体神经功能恢复情况。
随访时间 12~42 个月,平均 20.8 个月。两组患者性别比、年龄、吸烟史、糖尿病史、病程、突出椎间盘节段、足背伸肌力及术前 VAS 评分比较,差异均无统计学意义(P >0.05)。术后 1 周、4 周、12 周、12 个月,MeCbl+mNGF 组 VAS 评分均明显低于 MeCbl 组,差异有统计学意义(4.32 ±0.75 比 5.25 ±0.79、2.65 ±0.48 比 3.42 ±0.52、1.72 ±0.36 比 2.45 ±0.39、1.12 ±0.22 比 1.52 ±0.24,P <0.05)。术后 12 周、12 个月,MeCbl+mNGF 组感觉改善有效率明显高于 MeCbl 组,差异有统计学意义(90.48%比 52.00%、95.24%比 68.00%,P <0.05)。两组患者术后 1 周时肌力改善有效率比较,差异无统计学意义,但术后各时间点比较,差异均有统计学意义(61.90%比 32.00%、76.19%比 44.00%、80.95%比 48.00%,P <0.05)。
mNGF 可促进 LDH 合并足下垂患者神经功能的恢复,具有临床应用价值。